In individuals with asthma, pulmonary cAMP levels are reduced [21, 37], and cAMP-inducing reagents such as theophylline, PDE4 inhibitors, and β2 agonists can bolster lung function while inhibiting inflammation in animals and individuals with asthma [38–40]. This evidence concerns the gene PDE4A and asthma.